<DOC>
	<DOCNO>NCT02255110</DOCNO>
	<brief_summary>This Phase 2 , single-arm , Japanese multicenter trial evaluate safety , tolerability , efficacy TH-302 combination doxorubicin subject locally advanced unresectable metastatic soft tissue sarcoma ( STS ) .</brief_summary>
	<brief_title>A Japanese Trial TH-302 Subjects With Locally Advanced Unresectable Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Male female Japanese subject great equal ( &gt; = ) 15 year age Able understand purpose risk trial sign , appropriate , subject 's parent legal guardian sign write informed consent form approve Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) Pathologically confirm diagnosis STS histopathologic type specify protocol Locally advance unresectable metastatic disease standard curative therapy available treatment single agent doxorubicin consider appropriate Recovered reversible toxicity prior therapy Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) Version 1.1 ( least one target lesion outside previous radiation field progress within previous radiation field ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 3 month Acceptable liver function , renal function , hematologic status ( without growth factor support neutropenia transfusion dependency ) , cardiac function specify protocol All woman childbearing potential must negative serum pregnancy test subject must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel intrauterine device , intrauterine device [ IUD ] ) partner entry trial 6 month last dose . Postmenopausal woman must meet criterion 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum folliclestimulating hormone ( FSH ) level great ( &gt; ) 35 international unit per liter ( IU/L ) Low grade tumor accord standard grade system ( example , American Joint Committee Cancer [ AJCC ] Grade 1 2 Fédération Nationale de Centres de Lutte Contre le Cancer [ FNCLCC ] Grade 1 ) Prior systemic therapy advance metastatic STS ( neoadjuvant therapy follow surgical resection adjuvant therapy permit ) Prior STS therapy ifosfamide cyclophosphamide nitrogen mustard ; prior systemic therapy anthracycline anthracenedione ; prior mediastinal/cardiac radiotherapy Current use drug know cardiotoxicity know interaction doxorubicin Anticancer treatment radiation therapy , neoadjuvant adjuvant chemotherapy , targeted therapy , immunotherapy , hormone antitumor therapy within 4 week prior trial entry ( 6 week nitrosoureas mitomycin C ) . Significant cardiac dysfunction preclude treatment doxorubicin specify protocol Seizure disorder require anticonvulsant therapy unless seizurefree last year Known brain metastasis ( unless previously treat well controlled period &gt; =3 month screen ) Previously diagnose malignancy , except adequately treat nonmelanoma skin cancer , situ cancer , cancer subject diseasefree least 5 year screen Severe chronic obstructive pulmonary disease hypoxemia ( require supplementary oxygen , symptom due hypoxemia oxygen saturation &lt; 90 % pulse oximetry 2 minute walk ) opinion investigator physiological state likely cause normal tissue hypoxia Major surgery , diagnostic surgery , within 4 week prior Day 1 , without complete recovery Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Prior therapy hypoxic cytotoxin Subjects participate investigational drug device trial within 28 day prior trial entry Known infection human immunodeficiency virus ( HIV ) active infection hepatitis B hepatitis C Subjects exhibit allergic reaction structural compound similar TH302 drug product excipients Subjects take medication prolong QT interval risk Torsades de Pointes Subjects correct QT ( QTc ) interval calculate accord Bazett 's formula &gt; 450 millisecond ( msec ) base screen electrocardiogram ( ECG ) Subjects history long QT syndrome Subjects take medication moderate strong inhibitor inducer cytochrome P450 3A4 ( CYP3A4 ) Females pregnant breastfeeding Concomitant disease condition could interfere conduct study , would , opinion investigator , pose unacceptable risk subject study Unwillingness inability comply study protocol reason Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Locally Advanced Unresectable Metastatic Soft Tissue Sarcoma</keyword>
	<keyword>TH-302</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Evofosfamide</keyword>
</DOC>